News

Pyramid Biosciences’ $864 Million Licensing Deal

Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million. The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death. Founded in 2015, Waltham, Mass.-based...
Read more...

Groton biotech firm working on much-needed drug to treat stroke, brain injuries

A small drug development company that moved its headquarters from Cambridge, Mass., to the BioCT Innovations Commons on Shennecossett Road last year is aiming to have a huge impact on the treatment of strokes and brain injuries. Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Read more >>
Read more...

Wasabi Technologies and Nutanix Partner to Deliver Next-Gen Capacity Management and Analytics for Unstructured Data Storage

Wasabi Technologies, the hot cloud storage company, today announced that it has partnered with Nutanix, a leader in hybrid multicloud computing, to deliver a next-generation capacity management and analytics solution that meets the evolving needs for unstructured data storage. Through Nutanix Files supported integration of data tiering to Wasabi’s cloud object store, joint customers will be able to scale unstructured datasets on demand, deploy automated rules and triggers for efficient data management, and gain high-impact analytics and complete visibility across...
Read more...

Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP-002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options. MPS II is a rare genetic disease in children, which causes...
Read more...

Regroup Mass Notification Honored with 2021 ‘ASTORS’ Homeland Security Award for Best Mass Notification System

Regroup Mass Notification (http://www.regroup.com) today announced it is the recipient of a 2021 'ASTORS' Homeland Security Award from American Security Today for its mass notification solution. American Security Today's Annual 'ASTORS' Awards is the preeminent U.S. Homeland Security Awards Program, and today in its Sixth Year, continues to recognize industry leaders of Physical and Border Security, Cybersecurity, Emergency Preparedness - Management and Response, Law Enforcement, First Responders, as well as federal, state and municipal government agencies in the acknowledgment of...
Read more...

Parents – Do you Or Your Child Qualify for Public Service Loan Forgiveness?

The Biden Administration's temporary rule changes to the PSLF program are poised to impact hundreds of thousands of borrowers. "Since PSLF launched in 2007, only 16,000 participants have received forgiveness—but that's not for borrowers' lack of trying. Only 2.1 percent of applicants have been approved in the program's lifetime, which critics say is the result of rampant mismanagement, unfair review practices, and an inadequate program design from the start," says Laurel Taylor, CEO, FutureFuel.io, a platform designed to address student...
Read more...

Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers

Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing $4.1 million in a therapy aimed at helping patients who have failed standard therapy. The CIRM Board also approved investing $44,101,935 in 11 projects as part of...
Read more...

Wasabi Technologies Launches London Storage Region as it Ramps Up Global Expansion Plans

Wasabi Technologies, the hot cloud storage company, today announced the opening of a new storage region in London that will expand the availability and speed of services throughout the UK. Building on strong momentum for Wasabi in Europe following a major distribution partnership with Exclusive Networks, one of Europe's largest cybersecurity distributors, the London site also accelerates the company's rapid global expansion with plans to open additional storage regions in the next year. Read more >>
Read more...